Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6131156 | 0.92 | NPC1 (0.42) | CFTRMAPTNPC1POLB | |
| SCHEMBL5667295 | 0.86 | CFTR (0.43) | CFTRMAPTNPC1POLBTDP1 | |
| SCHEMBL5669025 | 0.86 | CFTR (0.45) | CFTRMAPTNPC1POLBTDP1 | |
| SCHEMBL5667450 | 0.84 | MAPT (0.36) | CFTRMAPTNPC1POLBTSHR | |
| SCHEMBL5668182 | 0.81 | NPC1 (0.43) | CFTRMAPTNPC1POLB | |
| SCHEMBL6131155 | 0.80 | MAPT (0.41) | CFTRMAPTNPC1POLBPTGDR2 | |
| SCHEMBL5667444 | 0.75 | LMNA (0.41) | MAPTLMNA | |
| SCHEMBL5668296 | 0.74 | CNR2 (0.40) | CFTRLMNA | |
| SCHEMBL13866135 | 0.74 | NPC1 (0.39) | CFTRMAPTNPC1F11LMNA | |
| SCHEMBL5667000 | 0.74 | NPC1 (0.41) | CFTRMAPTNPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148224-B2 | An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-12 | — | — | US | disclosed |
| US-20050176719-A1 | Novel pyrazinone derivatives | MSD K.K. (JP) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176719-A1 | Novel pyrazinone derivatives | CDK6, CDK4, CDK16 | CFTR 4573/4885MAPT 3834/4885NPC1 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.